InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-30 | 2026-04-01 | Christianson Mark | Business Development Director | Sale | 15.4K | $0.74 | $11K | 198.9K | View ↗ | |
| 2026-03-13 | 2026-03-16 | Christianson Mark | Business Development Director | Sale | 100 | $0.80 | $80.00 | 214.3K | View ↗ | |
| 2026-03-12 | 2026-03-16 | Christianson Mark | Business Development Director | Sale | 817 | $0.80 | $653.60 | 214.4K | View ↗ | |
| 2026-03-11 | 2026-03-12 | Christianson Mark | Business Development Director | Sale | 2,109 | $0.80 | $2K | 215.2K | View ↗ | |
| 2026-03-10 | 2026-03-12 | Christianson Mark | Business Development Director | Sale | 11.6K | $0.80 | $9K | 217.3K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Product revenue | $9.1M+163.5% | $3.5M+76.9% | $2.0M+1040.7% | $171K-3.9% | $178K |
| Cost of product revenue | $4.0M+66.7% | $2.4M+58.7% | $1.5M+518.2% | $242K-12.3% | $276K |
| Product gross profit | $5.1M+376.2% | $1.1M+136.5% | $457K+744.9% | -$71K+27.6% | -$98K |
| Collaborations revenue | $3.0M | — | — | $1.9M+2907.0% | $65K |
| Selling, general and administrative | $7.4M-6.5% | $7.9M+14.1% | $6.9M-0.8% | $7.0M+11.5% | $6.3M |
| Research and development | $5.0M-1.6% | $5.1M-27.0% | $6.9M+40.8% | $4.9M+25.6% | $3.9M |
| Total operating expenses | $12.4M-4.6% | $13.0M-6.5% | $13.9M+16.4% | $11.9M+16.9% | $10.2M |
| Loss from operations | -$4.2M+64.4% | -$11.9M+0.6% | -$12.0M-19.2% | -$10.0M+1.8% | -$10.2M |
| Fair value change in warrant liability | $785K+339.9% | -$327K | — | — | — |
| Financing costs | -$334K-45.9% | -$229K | — | — | — |
| Other income, net | $170K+36.2% | $125K+30.7% | $96K+207.4% | $31K | — |
| Loss before income taxes | -$3.6M+70.7% | -$12.3M-3.9% | -$11.9M-18.6% | -$10.0M | — |
| Net loss | -$3.6M+70.7% | -$12.3M-3.9% | -$11.9M-18.6% | -$10.0M-0.5% | -$9.9M |
| Basic (in Dollars per share) | -$0.09+80.4% | -$0.46+29.2% | -$0.65-3.2% | -$0.63+32.3% | -$0.93 |
| Diluted (in Dollars per share) | -$0.09+80.4% | -$0.46+29.2% | -$0.65 | — | — |
| Basic (in Shares) | $40.2M+50.0% | $26.8M+47.7% | $18.1M+13.3% | $16.0M+49.6% | $10.7M |
| Diluted (in Shares) | $40.2M+50.0% | $26.8M+47.7% | $18.1M | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
NeuroOne(R) to Present at the 2026 American Society for Stereotactic and Functional Neurosurgery Biennial Meeting on May 31, 2026
NeuroOne(R) Medical Technologies Announces Restatement of Financial Results for Quarter Ending March 31, 2026
NeuroOne Medical Technologies Corp (NMTC) Q2 2026 Earnings Call Highlights: Strong Product ...
NeuroOne Medical Technologies GAAP EPS of -$0.25 misses by $0.02, revenue of $2.4M misses by $0.18M